Latest Hotspot

Rhythm Pharmaceuticals Initiates Phase 2 Trial for Oral MC4R Agonist LB54640 in Hypothalamic Obesity Patients

30 July 2024
3 min read

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company actively engaged in commercial operations and dedicated to improving the lives of patients and families affected by rare neuroendocrine disorders, has reported that initial patients have received doses in its Phase 2 clinical study. This study is assessing the efficacy of LB54640, an experimental oral melanocortin-4 receptor (MC4R) agonist, in the treatment of hypothalamic obesity.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 应用程序

描述已自动生成

"Drawing from LG Chem's extensive preclinical work and promising outcomes from a Phase 1 trial, we view LB54640 as a potential effective oral therapy for MC4R pathway diseases without causing hyperpigmentation," stated David Meeker, M.D., Chair, Chief Executive Officer and President of Rhythm Pharmaceuticals. 

"We are eager to move forward with this molecule, aiming to provide a comprehensive range of treatment options for patients dealing with hyperphagia and severe obesity, ensuring they receive the most suitable therapy," added David Meeker.

The Phase 2 trial is designed as a randomized, placebo-controlled, double-blind study to evaluate the safety, weight loss, appetite suppression, and quality of life impacts of LB54640 in individuals aged 12 and above with hypothalamic obesity. Participants will receive a daily oral dose of either LB54640 or placebo for a duration of 14 weeks. The primary objective is to measure the change in body mass index from baseline after 14 weeks of treatment, with the possibility for patients to remain on therapy for up to 52 weeks.

Rhythm entered into a worldwide licensing agreement with LG Chem, Ltd. for LB54640 in January 2024. During a Phase 1 study involving healthy overweight adults, LB54640 showed dose-related weight loss and had a positive safety profile, with no alterations in blood pressure or heart rate and no signs of hyperpigmentation.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本

描述已自动生成

According to the data provided by the Synapse Database, As of July 30, 2024, there are 31 investigational drugs for the MC4R target, including 44 indications, 30 R&D institutions involved, with related clinical trials reaching 54, and as many as 4132 patents.

Bivamelagon is a small molecule drug with a specific focus on addressing rare diseases associated with MC4R dysregulation. Its advancement to Phase 2 underscores its potential as a treatment option for conditions such as hypothalamic obesity, proopiomelanocortin deficiency, leptin receptor deficiency, and obesity, offering hope to patients facing these challenging medical situations.

图形用户界面, 文本, 应用程序

描述已自动生成

Is Xenoview approved by the FDA?
Drug Insights
3 min read
Is Xenoview approved by the FDA?
30 July 2024
Xenoview received FDA approval on December 23, 2022. It plays a crucial role in providing clearer images of certain areas of the body, particularly the lungs, without the need for radiation exposure.
Read →
Enlivex Authorized for Phase I Trial of Allocetra in Psoriatic Arthritis Patients
Latest Hotspot
3 min read
Enlivex Authorized for Phase I Trial of Allocetra in Psoriatic Arthritis Patients
30 July 2024
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis.
Read →
Is Adstiladrin approved by the FDA?
Drug Insights
3 min read
Is Adstiladrin approved by the FDA?
30 July 2024
Adstiladrin received FDA approval on December 16, 2022. It represents a significant advancement in cancer therapy, particularly for patients who have not responded to standard treatments.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 26
Pharma Frontiers
11 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Jul 26
26 July 2024
Jul 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.